Every material Form 8-K Definitive Healthcare Corp. has filed with the SEC since September 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Definitive Healthcare reported third-quarter 2026 revenue of $54.7 million, down 9% from $60.0 million a year earlier, and Adjusted EBITDA of $15.7 million, down from $18.9 million. Its GAAP net loss narrowed to $5.4 million from $17.8 million, but the company will not give financial guidance or hold a call because its special committee received a non-binding acquisition proposal from Advent International.
Q3 2026 revenue was $54.7 million, down 9% from $60.0 million in Q3 2025.
Net loss was $5.4 million, compared with $17.8 million in Q3 2025; Adjusted Net Income was $8.8 million, compared with $9.7 million.
Adjusted EBITDA was $15.7 million, or 29% of revenue, compared with $18.9 million, or 32%, a year earlier.
The company will provide no financial guidance and no conference call, citing a non-binding Advent International indication of interest to acquire shares not already owned by Advent or founder Jason Krantz.
Definitive Healthcare disclosed that representatives of its tax receivable agreement (TRA) holders have irrevocably waived the right to an Early Termination Payment tied to any change of control with a definitive merger agreement signed on or before December 31, 2026. The TRA will terminate upon consummation of such a qualifying change of control, while TRA holders keep their other rights, including tax benefit payments for prior and current years.
Waiver covers change-of-control transactions with a definitive merger agreement executed on or before December 31, 2026.
Upon consummation of a qualifying change of control, the TRA terminates under its terms.
TRA holders keep rights to tax benefit payments for taxable years ending before, with, or including the transaction.
The company says it is not a party to the waiver; the filing gives no dollar amounts.
Definitive Healthcare said its special committee received a non-binding proposal dated September 1, 2026 from Advent International to acquire all shares not already owned by Advent or founder Jason Krantz for $1.02 per share in cash. The committee has not made a decision and there is no assurance a transaction will occur, so shareholders should note the proposal is preliminary.
Proposed all-cash price of $1.02 per Class A common share and an equivalent amount per Definitive OpCo Unit
Proposal is non-binding and dated September 1, 2026; announced September 2, 2026
Special Committee, advised by Rothschild & Co and Skadden, will review the proposal; no shareholder action is required now
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Definitive Healthcare Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →